Jason M. Broderick


Cabozantinib Improves Survival in Renal Cell Carcinoma

July 22, 2016

Data from the phase 3 METEOR trial presented at the 2016 annual meeting of the American Society of Clinical Oncology showed that cabozantinib reduced the risk of death in patients with advanced renal cell carcinoma by 34%, compared with everolimus.

Elotuzumab Combo Delays Myeloma Progression in Phase 3 Trial

July 16, 2015

A presscast held prior to the annual meeting of the American Society of Clincal Oncology presented interim results from the phase 3 ELOQUENT-2 trial. Adding elotuzumab to lenalidomide and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed-refractory multiple myeloma.